SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and other accredited investors, for gross proceeds of up to approximately $100 million. The initial closing of approximately $50 million of common stock at a price of $13.32 per share is ...

LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 12, 2025. Management will host a conference call and webcast at 8:30am EDT/13:30pm BST to discuss the company’s fina ...

Group 1 - Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies [1][3] - The company is participating in the H.C. Wainwright "HCW@Home" Series, with a fireside chat scheduled for July 30, 2025 [2] - Nkarta is advancing allogeneic, off-the-shelf NK cell therapies aimed at treating autoimmune diseases, utilizing a combination of cell expansion, cryopreservation, and CRISPR-based genome engineering [3] Group 2 - The event will be available via a simultaneous webcast on Nkarta's website, with a replay accessible for approximately 90 days [2] - Nkarta's approach is designed for deep therapeutic activity and broad access in outpatient treatment settings [3] - For further information, Nkarta's media and investor contact is Nadir Mahmood [4]

LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 360,550 shares of its common stock to 60 employees pursuant to the Company’s 2025 Inducement Plan. The stock options ...

Ready-made stem cell therapies for pets could be coming | TechCrunch https://t.co/ukOEqmlBkX ...

This presentation contains forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding profitability, growth in revenue, the commercial potential of our products, and objectives of the company, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," ...

Core Viewpoint - A new Florida law effective July 1, 2025, allows physicians to provide investigational stem cell therapies for orthopedics, wound care, and pain management, with strict safety and ethical standards in place [1][2]. Group 1: New Legislation - The law permits the use of stem cell therapies not yet approved by the FDA, with strict limits on the sources of stem cells, which must come from FDA-registered facilities [2][4]. - Physicians are required to obtain informed consent from patients before administering these therapies [2]. Group 2: Company Positioning - Celularity Inc. is prepared to supply ethically sourced stem cells for these treatments and has a facility that complies with the new law's requirements [2][4]. - The company has extensive knowledge and real-world data from clinical trials related to the therapies authorized under the new law [3][4]. Group 3: Industry Impact - The Florida Medical Association was involved in crafting the legislation to balance public protection against ineffective therapies and avoid overregulation of physicians [4]. - The law is seen as a potential model for other states, emphasizing the role of physicians in assessing the best therapeutic approaches for patients [4]. Group 4: Company Overview - Celularity Inc. specializes in regenerative and cellular medicine, focusing on placental-derived cell therapies and advanced biomaterial products [5]. - The company aims to address significant unmet global needs for effective and affordable therapies by utilizing the unique biology of the placenta [5].

CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advisory Board to a combined Scientific and Medical Advisory Board as the company advances toward clinical trials in ovarian cancer and autoimmune disease. This evolution marks a significant milestone in Ernexa’s transition from research to clinical-stage development. This come ...

Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiativesCAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that the Company completed the second closing under the previously announced securities purchase agreement (the “SPA”) entered into on March 31, 2025 with certain accredited investors. The c ...

Core Insights - Lyell Immunopharma, Inc. is participating in the H.C. Wainwright "HCW@Home" Series on June 25, 2025, to discuss new clinical data for its lead product candidate LYL314 [1][2] Group 1: Company Overview - Lyell Immunopharma is a clinical-stage company focused on next-generation CAR T-cell therapies for cancer patients, particularly those with hematologic malignancies and solid tumors [4] - The company utilizes advanced technologies to enhance CAR T cells, aiming for durable tumor cytotoxicity and long-lasting clinical responses [4] - Lyell's manufacturing facility, the LyFE Manufacturing Center™, has the capacity to produce over 1,200 CAR T-cell doses at full capacity [4] Group 2: Product Candidate Details - LYL314 is an autologous dual-targeting CD19/CD20 CAR T-cell product candidate, currently in pivotal-stage development for patients with relapsed and/or refractory large B-cell lymphoma (LBCL) [2] - The product has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. FDA, indicating its potential clinical benefits [2] - LYL314 aims to improve complete response rates and prolong the duration of responses compared to existing CD19-targeted CAR T-cell therapies for LBCL [2]